[Role of the Rho-kinase pathway in pulmonary arterial hypertension].
Yoshihiro
Y
Fukumoto
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000077300:Bosentan; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D051379:Mice; D058990:Molecular Targeted Therapy; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D051381:Rats; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D014655:Vascular Resistance / Q000187:drug effects; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology*
D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; C048081:beraprost; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D054460:rho-Associated Kinases; C049347:fasudil; D000077300:Bosentan